HLB Co., Ltd. (KOSDAQ:028300)
South Korea · Delayed Price · Currency is KRW 63,700
-4,500 (-6.60%)
Apr 16, 2026, 3:30 PM KST
HLB Co., Ltd. Revenue
In the year 2025, HLB Co., Ltd. had annual revenue of 84.17B KRW with 23.55% growth. HLB Co., Ltd. had revenue of 28.66B in the quarter ending December 31, 2025, with 13.64% growth.
Revenue
84.17B
Revenue Growth
+23.55%
P/S Ratio
107.66
Revenue / Employee
550.15M
Employees
153
Market Cap
9.06T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.17B | 16.05B | 23.55% |
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 3.02T |
| SK Biopharmaceuticals | 706.74B |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| ALTEOGEN | 215.86B |
| LigaChem Biosciences | 141.55B |
| OliX Pharmaceuticals | 14.67B |